Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Neurodegenerative diseases are becoming major challenges throughout the globe at present scenario. The past decade has seen tremendous efforts in biomarker discovery and validation for neurodegenerative diseases. The source and type of biomarkers has continued to grow for central nervous system diseases, from biofluid-based biomarkers.
While DNA remains a predominant biomarker used to identify familial forms of neurodegenerative diseases, various types of RNA have more recently been linked to familial and sporadic forms of neurodegenerative diseases during the past few years. Imaging approaches continue to evolve and are making major contributions to target engagement and early diagnostic biomarkers.
Incorporation of biomarkers into drug development and clinical trials for neurodegenerative diseases promises to aid in the development and demonstration of target engagement and drug efficacy for neurologic disorders. In this special issue we focus on to disseminate recent advancements in developing biomarkers for clinical utility in neurodegenerative diseases and aid to the scientific community in the realm of cognitive neuroscience.
Submission process: You may submit manuscript though online at https://www.editorialmanager.com/pharma/ send as an e-mail attachment to the Editorial Office at [email protected] (or) [email protected]